Core Viewpoint - Heng Rui Medicine (01276) has received the acceptance notice from the National Medical Products Administration for the marketing authorization application of injectable toremifene, indicating progress in its product pipeline [1] Group 1: Product Development - The injectable toremifene has been approved for indications including sedation and anesthesia during non-tracheal intubation surgeries and for induction and maintenance of general anesthesia [1] - The application for market approval is based on two key studies focused on sedation for mechanically ventilated patients in the Intensive Care Unit (ICU) [1] Group 2: Clinical Research - The HR7056-302 study is a Phase III clinical trial evaluating toremifene compared to standard first-line treatments for short-term sedation during critical care, involving 214 patients across 43 centers, led by Professor Guan Xiangdong from Sun Yat-sen University First Affiliated Hospital [1] - The HR7056-206 study is a multi-center Phase II clinical trial assessing toremifene for long-term sedation in critical care, with 24 patients enrolled from 18 centers, led by Professor Shen Feng from Guizhou Medical University Affiliated Hospital [1] - Both studies achieved their primary endpoints as expected [1]

Core Viewpoint - Heng Rui Medicine (01276) has received acceptance from the National Medical Products Administration for its drug application of Haequparbopamine tablets, aimed at treating adults and children aged 6 and above with persistent and chronic primary immune thrombocytopenia (ITP) who have had inadequate responses to corticosteroids and immunoglobulins [1] Group 1 - The drug application for Haequparbopamine tablets is specifically for patients with primary immune thrombocytopenia (ITP) who have not responded well to previous treatments [1] - The Phase III clinical trial (HR-TPO-ITP-III-PED) for Haequparbopamine tablets achieved its primary endpoint as planned in March 2025 [1] - The study was a multicenter, randomized, double-blind, and open-label Phase III trial evaluating the efficacy and safety of Haequparbopamine tablets in children and adolescents with ITP, led by Professor Wang Tianyou from Beijing Children's Hospital [1] Group 2 - A total of 100 cases of children and adolescents aged 6 and above with primary immune thrombocytopenia were enrolled in the trial [1] - The treatment group showed significant superiority over the control group in achieving the primary endpoint [1] - Long-term treatment demonstrated good safety and efficacy [1]

Core Viewpoint - Huadong Medicine (000963.SZ) announced that its wholly-owned subsidiary, Sino-American Huadong, received the Acceptance Notice from the National Medical Products Administration for the marketing authorization application of Edaravone Tablets (R&D code: TTYP01) for the treatment of acute ischemic stroke [1] Group 1 - Sino-American Huadong has signed an exclusive licensing agreement with Ausgen Biotech, obtaining exclusive rights for all indications of TTYP01 in mainland China, Hong Kong, Macau, and Taiwan [1]

Core Viewpoint - Huadong Medicine's subsidiary, Sino-American Huadong, has received a notice of acceptance from the National Medical Products Administration for its application to market edaravone tablets for the treatment of acute ischemic stroke [1] Group 1: Company Developments - The application for edaravone tablets (R&D code: TTYP01) has been officially accepted, indicating progress in the drug approval process [1] - Edaravone is considered a significant drug in the neurology field, highlighting the company's focus on innovative treatments [1] Group 2: Industry Implications - The oral formulation of edaravone tablets is expected to reduce the consumption of medical resources compared to the intravenous administration of edaravone, which is typically given in hospitals for 14 days [1] - The ability for patients to self-administer the oral tablets may enhance treatment adherence and improve patient outcomes in the long term [1]

Core Viewpoint - Changshan Pharmaceutical's application for the marketing authorization of Abemaciclib injection for type 2 diabetes has been accepted, but there is uncertainty regarding its approval and timeline [1] Group 1: Stock Performance - The company's stock price has deviated significantly, with a cumulative increase of 147.69% from May 6 to June 9, which is over 30% deviation from the industry and ChiNext index growth [1] Group 2: Product Development - The application for clinical trials of Abemaciclib injection for weight loss indications has also been accepted, but there is uncertainty about receiving the approval notice [1]

Core Viewpoint - The company has submitted a drug registration application for Ensartinib capsules to the Macau Drug Administration, aiming to treat patients with locally advanced or metastatic non-small cell lung cancer who are positive for anaplastic lymphoma kinase (ALK) [1] Group 1 - The drug, marketed as Baimena, is a new generation ALK inhibitor developed in collaboration with the company's subsidiary, Xcovery [1] - Ensartinib has already received marketing approval in China and the United States, and the company is advancing the application process in Europe [1] - The company will continue to monitor the review progress, and the short-term impact of this application on the company's operating performance is not expected to be significant [1]

Core Viewpoint - Zhongguancun announced that its subsidiary Shandong Huasu Pharmaceutical Co., Ltd. has had its application for the listing permit of Bisoprolol Amlodipine Tablets accepted by the National Medical Products Administration, which is a combination therapy for hypertension treatment [1] Group 1 - The drug is a fixed-dose combination formulation of fumarate bisoprolol 5mg and amlodipine besylate (calculated as amlodipine) 5mg [1] - The project has accumulated research and development expenses of 6.0798 million yuan [1] - Shandong Huasu will actively promote the subsequent review work, and if the listing permit is successfully obtained, it will enhance its market competitiveness [1]